News
Video
Author(s):
Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.